{
    "name": "belantamab mafodotin",
    "comment": "Rx",
    "other_names": [
        "Blenrep",
        "belantamab mafodotin-blmf"
    ],
    "classes": [
        "Anti-BCMA Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/blenrep-belantamab-mafodotin-4000056",
    "pregnancy": {
        "common": [
            "Based on its mechanism of action, fetal harm may occur when administered to pregnant females; contains genotoxic compound (the microtubule inhibitor, monomethyl auristatin phenylalanine [MMAF]) that targets actively dividing cells",
            "Human IgG is known to cross the placenta; therefore, belantamab mafodotin has the potential to be transmitted from mother to developing fetus",
            "No data available on use in pregnant females to evaluate for drug-associated risks",
            "No animal reproduction studies were conducted",
            "Advise pregnant females of potential risks ",
            "Recommend pregnancy testing for females of reproductive potential before initiating treatment "
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 4 months after last dose",
                    "Males with female partners of reproductive potential: Use effective contraception during treatment and for 6 months after last dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on findings in animal studies, may impair fertility in females and males",
                    "Effects were not reversible in male rats, but were reversible in female rats"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no data on presence in human milk or effects on breastfed children or milk production",
            "Advise women not to breastfeed during treatment and for 3 months after last dose "
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Ocular toxicity",
                    "description": [
                        "May cause corneal epithelium changes resulting in vision changes, including severe vision loss, corneal ulcer, and visual symptoms (eg, blurred vision, dry eyes)",
                        "Conduct ophthalmic examinations at baseline, before each dose, and promptly for worsening symptoms",
                        "Withhold until improvement and resume, or permanently discontinue, based on severity ",
                        "Owing to ocular toxicity, available only through a restricted program under a REMS program called the BLENREP REMS"
                    ]
                },
                {
                    "type": "Blenrep REMS",
                    "description": [
                        "Notable requirements include the following:",
                        "Prescribers must be certified with the program by enrolling and completing training",
                        "Prescribers must counsel patients about risk of ocular toxicity and need for ophthalmic examinations before each dose",
                        "Patients must be enrolled and comply with monitoring",
                        "Healthcare facilities must be certified with the program and verify patients are authorized to receive belantamab mafodotin",
                        "Wholesalers and distributors must only distribute to certified healthcare facilities",
                        "Further information is available, at ",
                        "www.BLENREPREMS.com",
                        " and 1-855-209-9188"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Severe ocular adverse reactions occurred in clinical trials; changes in visual acuity may be associated with difficulty driving and reading; advise patients to use caution when driving or operating machinery; only available through restricted REMS program",
                "Thrombocytopenia reported; perform CBC counts at baseline and during treatment as clinically indicated",
                "Infusion-related reactions reported; monitor for infusion-related reactions; if reactions occurs, administer premedication for all subsequent infusion",
                "May cause fetal harm when administered to pregnant females"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Keratopathy",
            "percent": "71"
        },
        {
            "name": "Platelets decreased",
            "percent": "62"
        },
        {
            "name": "AST increased",
            "percent": "57"
        },
        {
            "name": "Decreased visual acuity",
            "percent": "53"
        },
        {
            "name": "Lymphocytes decreased",
            "percent": "49"
        },
        {
            "name": "Albumin decreased",
            "percent": "43"
        },
        {
            "name": "Glucose increased",
            "percent": "38"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "32"
        },
        {
            "name": "Creatinine increased",
            "percent": "28"
        },
        {
            "name": "Neutrophils decreased",
            "percent": "28"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": "26"
        },
        {
            "name": "Gamma",
            "percent": "25"
        },
        {
            "name": "glutamyl transferase increased",
            "percent": "24"
        },
        {
            "name": "Nausea",
            "percent": "22"
        },
        {
            "name": "Blurred vision",
            "percent": "22"
        },
        {
            "name": "Pyrexia",
            "percent": "22"
        },
        {
            "name": "Creatinine phosphokinase increased",
            "percent": "21"
        },
        {
            "name": "Sodium decreased",
            "percent": "21"
        },
        {
            "name": "Infusion",
            "percent": "20"
        },
        {
            "name": "related reactions",
            "percent": "20"
        },
        {
            "name": "Fatigue",
            "percent": "14"
        },
        {
            "name": "Potassium decreased",
            "percent": "13"
        },
        {
            "name": "Dry eyes",
            "percent": "13"
        },
        {
            "name": "Constipation",
            "percent": "12"
        },
        {
            "name": "Diarrhea",
            "percent": "12"
        },
        {
            "name": "Arthralgia",
            "percent": "11"
        },
        {
            "name": "Decreased appetite",
            "percent": "11"
        },
        {
            "name": "Back pain",
            "percent": "44"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "28"
        },
        {
            "name": "Keratopathy",
            "percent": "22"
        },
        {
            "name": "Decreased visual acuity",
            "percent": "21"
        },
        {
            "name": "Lymphocytes decreased",
            "percent": "18"
        },
        {
            "name": "Platelets decreased",
            "percent": "10"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "10"
        },
        {
            "name": "Photophobia",
            "percent": "10"
        },
        {
            "name": "Eye irritation",
            "percent": "10"
        },
        {
            "name": "Infective keratitis",
            "percent": "10"
        },
        {
            "name": "Ulcerative keratitis",
            "percent": "10"
        },
        {
            "name": "Vomiting",
            "percent": "10"
        },
        {
            "name": "Pneumonia",
            "percent": "9"
        },
        {
            "name": "Albuminuria",
            "percent": "5"
        },
        {
            "name": "Neutrophils decreased",
            "percent": "5"
        },
        {
            "name": "Creatinine increased",
            "percent": "4"
        },
        {
            "name": "Gamma",
            "percent": "4"
        },
        {
            "name": "glutamyl transferase increased",
            "percent": "3"
        },
        {
            "name": "Blurred vision",
            "percent": "3"
        },
        {
            "name": "Albumin decreased",
            "percent": "3"
        },
        {
            "name": "Infusion",
            "percent": "2"
        },
        {
            "name": "related reactions",
            "percent": "2"
        },
        {
            "name": "Pyrexia",
            "percent": "2"
        },
        {
            "name": "Glucose increased",
            "percent": "2"
        },
        {
            "name": "AST increased",
            "percent": "2"
        },
        {
            "name": "Sodium decreased",
            "percent": "1"
        },
        {
            "name": "Potassium decreased",
            "percent": "1"
        },
        {
            "name": "Fatigue",
            "percent": "1"
        },
        {
            "name": "Back pain",
            "percent": "1"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": null
        },
        {
            "name": "Creatinine phosphokinase increased",
            "percent": null
        },
        {
            "name": "Dry eyes",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        }
    ]
}